Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BY 4.0Eurosurveillance

Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023

  1. 1National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia
  2. 2The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia

Abstract

BACKGROUND: Modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine is used globally for disease prevention. Real-world safety data following co-administration of MVA-BN with other vaccines is limited.

AIM: To characterise the adverse event profile of MVA-BN given alone or concomitantly with other vaccines using data from Australia’s active vaccine safety surveillance (AusVaxSafety).

METHODS: Individuals (≥ 18 years) who received MVA-BN between 30 August 2022 and 20 April 2023 at sentinel AusVaxSafety surveillance sites and registered via QR code were surveyed on days 7 and 14 post-vaccination regarding adverse events following immunisation (AEFI), medical review by a healthcare professional and impact on daily activities. Analyses included participants who completed both surveys. Outcomes were compared by administration route, dose and concomitant vaccination status.

RESULTS: Among 10,943 participants (response rate: 46%; 97% male), 200 (1.8%) received at least one concomitant vaccine. Across 14 days, AEFI rates were comparable or lower in concomitant recipients following intradermal administration (alone: 56% (Dose 1), 36% (Dose 2) vs concomitant: 53% (Dose 1), 32% (Dose 2)) and subcutaneous administration (alone: 49% (Dose 1), 32% (Dose 2) vs concomitant: 28% (Dose 1) and 24% (Dose 2)). Medical review was uncommon (0–2.7%). Impact on daily activities was low across groups (6% vs 3.5%), with most symptoms lasting ≤ 1 day.

CONCLUSION: The frequency and severity of AEFIs within 14 days post-vaccination were similar between concomitant and non-concomitant group. These findings provide preliminary, exploratory evidence supporting the safe co-administration of MVA-BN with other adult vaccines, primarily in adult men, and may help inform future immunisation policy and public health recommendations.

Related

  1. Receptor-guided engineering of oncolytic vaccinia creates a synthetic support niche for off-the-shelf NK cell therapy
    R. Rezaei, Z. Gan, N. Akeem Akilimali +12
    bioRxivPreprintAll rights reservedFull textSystems & synthetic biologybioRxiv
  2. Morphological changes in the eyelid following modified rotational suturing combined with lower eyelid margin fixation for the correction of congenital lower eyelid epiblepharon
    Yao Lai, Jincheng Liu, Mengling Zhou +4
    BMC OphthalmologyPeer-reviewedCC BYFull textGenetics & genomicsDOAJ
  3. The bisbenzimide compound ridinilazole has antiviral activity against vaccinia and mpox viruses.
    Misbah El-Jesr, Lucy Eke, Blair L. Strang +2
    The Journal of general virologyPeer-reviewedCC BYFull textMicrobiologyEurope PMCPMC
  4. Interleukin-21 expressing oncolytic vaccinia virus elicits systemic anti-tumor immune response and synergizes with immunotherapies
    Rong Zhang, Tingting Wang, Yu Wang +7
    Molecular Therapy: OncologyPeer-reviewedCC BYFull textGenetics & genomicsDOAJEurope PMCPMC
  5. The selection for cidofovir-resistant mutant vaccinia viruses is inhibited by coinfecting cidofovir-sensitive wildtypes
    S. Z. Lee, Y.-C. Lin, D. H. Evans +1
    bioRxivPreprintCC BY-NC-NDFull textMicrobiologybioRxiv
BibTeX
@article{nguyen2026shortterm,
  title = {{Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023}},
  author = {Thuy Nguyen and Kristine Macartney and Nicholas Wood and Lucy Dawes and Lucy Deng},
  journal = {Eurosurveillance},
  year = {2026},
  month = nov,
  doi = {10.2807/1560-7917.es.2026.31.44.2600181},
  url = {https://doi.org/10.2807/1560-7917.es.2026.31.44.2600181},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023
AU  - Thuy Nguyen
AU  - Kristine Macartney
AU  - Nicholas Wood
AU  - Lucy Dawes
AU  - Lucy Deng
PY  - 2026
DA  - 2026/11/05
JO  - Eurosurveillance
DO  - 10.2807/1560-7917.es.2026.31.44.2600181
UR  - https://doi.org/10.2807/1560-7917.es.2026.31.44.2600181
AB  - BACKGROUND: Modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine is used globally for disease prevention. Real-world safety data following co-administration of MVA-BN with other vaccines is limited.  AIM: To characterise the adverse event profile of MVA-BN given alone or concomitantly with other vaccines using data from Australia’s active vaccine safety surveillance (AusVaxSafety).  METHODS: Individuals (≥ 18 years) who received MVA-BN between 30 August 2022 and 20 April 2023 at sentinel AusVaxSafety surveillance sites and registered via QR code were surveyed on days 7 and 14 post-vaccination regarding adverse events following immunisation (AEFI), medical review by a healthcare professional and impact on daily activities. Analyses included participants who completed both surveys. Outcomes were compared by administration route, dose and concomitant vaccination status.  RESULTS: Among 10,943 participants (response rate: 46%; 97% male), 200 (1.8%) received at least one concomitant vaccine. Across 14 days, AEFI rates were comparable or lower in concomitant recipients following intradermal administration (alone: 56% (Dose 1), 36% (Dose 2) vs concomitant: 53% (Dose 1), 32% (Dose 2)) and subcutaneous administration (alone: 49% (Dose 1), 32% (Dose 2) vs concomitant: 28% (Dose 1) and 24% (Dose 2)). Medical review was uncommon (0–2.7%). Impact on daily activities was low across groups (6% vs 3.5%), with most symptoms lasting ≤ 1 day.  CONCLUSION: The frequency and severity of AEFIs within 14 days post-vaccination were similar between concomitant and non-concomitant group. These findings provide preliminary, exploratory evidence supporting the safe co-administration of MVA-BN with other adult vaccines, primarily in adult men, and may help inform future immunisation policy and public health recommendations.
SN  - 1025-496X
SN  - 1560-7917
ER  -